BioCryst Pharmaceuticals Inc (BCRX) — Capital Reinvestment Ratio

Latest as of December 2025: 0.00x

BioCryst Pharmaceuticals Inc (BCRX) has a Capital Reinvestment Ratio of 0.00x as of December 2025, meaning it reinvests 0% of its operating cash flow ($276.04 Million) in capital expenditures ($802.00K). See BioCryst Pharmaceuticals Inc balance sheet independence to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.00x

Capex / Operating Cash Flow

Operating Cash Flow

$276.04 Million

USD

Capital Expenditures

$802.00K

USD

Data as of

Dec 2025

Most recent filing

BioCryst Pharmaceuticals Inc Capital Reinvestment Ratio (2025–2025)

This chart tracks BioCryst Pharmaceuticals Inc's Capital Reinvestment Ratio across 1 annual periods. Check BioCryst Pharmaceuticals Inc (BCRX) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for BioCryst Pharmaceuticals Inc (2025–2025)

Year-by-year Capital Reinvestment Ratio for BioCryst Pharmaceuticals Inc from 2025 to 2025. For live market cap and broader valuation context, see BioCryst Pharmaceuticals Inc (BCRX) total market value.

Year	Reinvestment Ratio	Operating CF (USD)	Capital Expenditures	YoY Change
2025	0.01x	$329.88 Million	$2.47 Million	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow